Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Research

Quantum-Si and Researchers to Present Next-Gen Protein Sequencing™ at US HUPO 2025

  • The Pharma Data
  • February 14, 2025

Quantum-Si and Leading Researchers to Showcase Advances in Next-Generation Protein Sequencing™ at US HUPO 2025 Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or “the Company”), renowned as The Protein Sequencing Company™,…

Read MoreQuantum-Si and Researchers to Present Next-Gen Protein Sequencing™ at US HUPO 2025
  • Research

RenovoRx Showcases Promising Preclinical Data on TAMP™ Drug Delivery

  • The Pharma Data
  • February 14, 2025

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath device, recently showcased its latest pre-clinical data…

Read MoreRenovoRx Showcases Promising Preclinical Data on TAMP™ Drug Delivery
  • Press Releases

Newleos Launches with $93.5M to Advance Neuropsychiatric Treatments

  • The Pharma Data
  • February 14, 2025

Newleos Launches with $93.5M to Advance Neuropsychiatric Treatments Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development, has announced the successful…

Read MoreNewleos Launches with $93.5M to Advance Neuropsychiatric Treatments
  • News

Ensoma Secures Rare Pediatric Disease & Orphan Drug Status for EN-374 in Chronic Granulomatous Disease

  • The Pharma Data
  • February 14, 2025

Ensoma Secures Rare Pediatric Disease & Orphan Drug Status for EN-374 in Chronic Granulomatous Disease Ensoma, a genomic medicines company pioneering in vivo therapies to engineer the hematopoietic system, has…

Read MoreEnsoma Secures Rare Pediatric Disease & Orphan Drug Status for EN-374 in Chronic Granulomatous Disease
  • Research

Latent Labs Raises $50M to Advance AI-Driven Programmable Biology

  • The Pharma Data
  • February 14, 2025

Latent Labs Secures $50 Million to Pioneer AI-Driven Programmable Biology Latent Labs, an emerging leader in AI-powered biological programming, has officially stepped out of stealth mode, announcing a significant $50…

Read MoreLatent Labs Raises $50M to Advance AI-Driven Programmable Biology
  • Regulatory

Opna Bio’s OPN-6602 Gains Orphan Drug Status for Multiple Myeloma

  • The Pharma Data
  • February 13, 2025

Opna Bio Secures Orphan Drug Designation for OPN-6602 in Multiple Myeloma Opna Bio, a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative oncology therapeutics, has announced that…

Read MoreOpna Bio’s OPN-6602 Gains Orphan Drug Status for Multiple Myeloma
  • News

AltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors

  • The Pharma Data
  • February 13, 2025

AltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying treatments and detection tools for amyloid diseases, has…

Read MoreAltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors
  • Research

Tivic Health Secures Global Rights to Phase III TLR5 Agonist from Statera Biopharma

  • The Pharma Data
  • February 13, 2025

Tivic Health Secures Global Rights to Phase III TLR5 Agonist from Statera Biopharma Tivic Health Systems, Inc. (Nasdaq: TIVC) has taken a major step toward expanding its therapeutic portfolio by…

Read MoreTivic Health Secures Global Rights to Phase III TLR5 Agonist from Statera Biopharma
  • News

Real-World Outcomes Data for ADSTILADRIN® to Be Presented at 2025 ASCO Genitourinary Symposium

  • The Pharma Data
  • February 13, 2025

Real-World Outcomes Data for ADSTILADRIN® to Be Presented at 2025 ASCO Genitourinary Symposium Ferring Pharmaceuticals recently announced that three abstracts showcasing ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025…

Read MoreReal-World Outcomes Data for ADSTILADRIN® to Be Presented at 2025 ASCO Genitourinary Symposium
  • News

Alto Neuroscience Reports Positive Interim Results from ALTO-300 Phase 2b MDD Trial

  • The Pharma Data
  • February 13, 2025

Alto Neuroscience Reports Positive Interim Analysis Outcome for ALTO-300 Phase 2b Trial in Major Depressive Disorder Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on developing precision…

Read MoreAlto Neuroscience Reports Positive Interim Results from ALTO-300 Phase 2b MDD Trial
  • Business

Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug

  • The Pharma Data
  • February 13, 2025

Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug Abcuro, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat autoimmune diseases and cancer by precisely…

Read MoreAbcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug
  • Research

Seaport Therapeutics Publishes Research on Glyph™ Platform’s 55% Lymphatic Drug Absorption

  • The Pharma Data
  • February 13, 2025

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company specializing in novel neuropsychiatric medicines, has announced the publication of groundbreaking research on its Glyph™ platform. The study, published in…

Read MoreSeaport Therapeutics Publishes Research on Glyph™ Platform’s 55% Lymphatic Drug Absorption
PrevNext
UK Biotech Day
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • UCB Expands Immunology Portfolio with Acquisition of Candid Therapeutics, Advancing Novel T-Cell Engager Strategy
  • J&J Statement on FDA Approval of STELARA® for Pediatric Crohn’s Disease
  • Incyte Wins FDA Approval for Jakafi XR™ Extended-Release Tablets Across Multiple Hematologic Indications
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.